Novogen Limited’s subsidiary, Marshall Edwards, Inc., (NASDAQ: MSHL) has announced today the appointment of Mr Thomas Zech as its CFO and Company Secretary based in San Diego.  This follows the appointment of Dr Daniel Gold as CEO of Marshall Edwards, Inc., in April 2010 and is part of the continuing strategy to focus the Group’s resources towards oncology drug research and development.

Following these appointments Novogen has restructured its Australian management team and has appointed Mr Mark Hinze as CFO and Operations Manager of Novogen.  Mr Hinze has been with the Novogen Group for over 10 years and previously held the position of the Group’s Financial Controller.

Mr David Seaton who was previously CFO of Novogen and CFO and Company Secretary of Marshall Edwards, Inc., and more recently Acting CEO will leave the Company.  During the transition period however, his services will be available to the Company on a consulting basis.  Also, due to the high priority of current and future clinical programs, now being managed from the US, Novogen’s Group Director of Research Professor Alan Husband will leave the Group at the end of June 2010.

“We are all grateful for the significant contribution Professor Husband and Mr Seaton have made to the Group and wish them well in their future endeavours” said Philip Johnston, Chairman of the Board, Novogen Limited.

Mr Johnston also said “following the results of OVATURE the Novogen Board has been conducting an exhaustive review of all options available to it to ensure shareholder value is maximised.  These include structural options and changes to the composition of the Board and it expects to provide further information in the months ahead as these plans are finalised”.

A number of other management changes will also take effect from the end of June as part of the restructure.

In the meantime, Novogen staff will continue to work closely with Marshall Edwards in developing the Group’s cancer compounds, and will continue to provide Marshall Edwards with administration and technical services.  In addition, Novogen will continue to seek opportunities to develop its Glucan technology and to maximise shareholder value from its Consumer Health Care business.

Novogen Limited (ASX: NRT; NASDAQ: NVGN) is an Australian biotechnology company based in Sydney, Australia. The company has a Consumer Healthcare business and a Pharmaceutical Division developing a range of oncology therapeutics from its proprietary flavonoid synthetic chemistry technology platform. More information the Novogen Group of companies can be found at www.novogen.com.